Prescription drug monitoring programs (PDMPs) have emerged as statelevel interventions designed to curb opioid abuse and overprescription. Although some states have voluntary PDMPs, others have enacted mandatory or “must-access” programs where authorized individuals must consult the PDMP before prescribing certain controlled substances. An analysis published in Contemporary Economic Policy reveals that mustaccess PDMP implementation will not uniformly reduce prescription retail opioid sales across eight commonly prescribed opioids.
Must-access PDMP implementation had no statistically significant influence on the retail sales of the procedure drugs methadone and buprenorphine.
The findings claim that PDMP implementation is most beneficial considered as section of a broader policy reaction to the opioid crisis.
“AMERICA opioid epidemic is really a complex problem. These results claim that must-access PDMP implementation alone cannot fully address the general public health issues connected with this ongoing public health crisis,” said corresponding author Collin Hodges, Ph.D., of the University of Central Arkansas.
More info: Shishir Shakya et al, Mustaccess prescription drug monitoring programs and retail opioid sales, Contemporary Economic Policy (2022). DOI: 10.1111/coep.12586
Citation: Do mandatory prescription drug monitoring programs effectively reduce opioid sales? (2022, September 8) retrieved 8 September 2022 from https://medicalxpress.com/news/2022-09-mandatory-prescription-drug-effectively-opioid.html
This document is at the mercy of copyright. Aside from any fair dealing for the intended purpose of private study or research, no part could be reproduced minus the written permission. This content is provided for information purposes only.